FAS and cancer: The DR TRAIL-R1/2 and CD95 (also known as FAS) contribute to the immunosurveillance towards cancer or infected cells by their ability to induce cell death upon engagement by their ligand, TRAIL and CD95L, respectively (Von Karstedt et al, 2017; Rossin et al, 2019; Risso et al, 2022).